Receptor News and Research

RSS

Speakers Announced for Virtual Experimental Biology 2021 Meeting

Renowned scientists—including Nobel laureates, research pioneers, and celebrated educators—will speak at the virtual Experimental Biology (EB) 2021 meeting, to be held April 27–30.

23 Mar 2021

Study suggests SARS-CoV-2 antibodies in breast milk are robust, neutralizing and durable

A new study addresses the issue of passive immunity to SARS-CoV-2 for newborns via breast milk.

23 Mar 2021

Dandelion extract inhibits SARS-CoV-2 in vitro

An exciting new study describes a specific inhibitor of the SARS-CoV-2 found in an extract of the common dandelion that could provide a new and fruitful avenue of drug research.

23 Mar 2021

IONTAS identifies novel SARS-CoV-2 neutralising antibodies

IONTAS Limited (IONTAS) and FairJourney Biologics S.A (FJB)., leaders in the discovery and optimization of fully human antibodies, have announced the identification of neutralizing antibodies, which bind to multiple emerging SARS-CoV-2 variants.

From FairJourney Biologics 23 Mar 2021

Researchers use layered double hydroxide to increase neuronal growth in mice with spinal cord injuries

Researchers from the Department of Orthopedics of Tongji Hospital at Tongji University in Shanghai have successfully used a nanobiomaterial called layered double hydroxide (LDH) to inhibit the inflammatory environment surrounding spinal cord injuries in mice, accelerating regeneration of neurons and reconstruction of the neural circuit in the spine.

23 Mar 2021

Ai helps identify critical interactions for SARS-CoV-2 spike protein binding to ACE2

Recently, researchers from the US employed multiple-µs molecular dynamic simulations to compare the relative dynamics, stabilities, and energy differences between the SARS-CoV receptor-binding domain (RBD)-ACE2 and SARS-CoV-2 RBD-ACE2 complexes. The study is published on the preprint server, bioRxiv.

23 Mar 2021

Single BNT162b2 mRNA dose induces humoral and T cell responses against mutated variants with a history of COVID-19

In a paper recently uploaded to the preprint server bioRxiv by Tauzin et al. (March 18th, 2021) the ability of a single dose of mRNA vaccine to induce humoral and T cell responses against mutated variants are demonstrated and found to be reinforced in individuals with a history of COVID-19.

22 Mar 2021

Simple SARS-CoV-2 mutations allow escape from the majority of polyclonal antibodies

The group identified a single class of antibodies that target a particular epitope on the RBD of SARS-CoV-2, suggesting that the human polyclonal response to SARS-CoV-2 infection is dominated by a worryingly narrow range of antibodies that target an epitope undergoing rapid mutation.

22 Mar 2021

Star-shaped brain cells impact the length and depth of sleep in mice

For something we spend one-third of our lives doing, we still understand remarkably little about how sleep works -- for example, why can some people sleep deeply through any disturbance, while others regularly toss and turn for hours each night? And why do we all seem to need a different amount of sleep to feel rested?

22 Mar 2021

Virginia Tech neuroscientist uses NIH grant to understand astrocytic processes in the healthy brain

Of all the worlds still to be explored, among the most mysterious may be closest to home. Indeed, it may be right between your ears.

22 Mar 2021

SARS-CoV-2 infection is circadian

An international team of researchers has found that angiotensin-converting enzyme 2 (ACE2) levels in lung cells vary over the day, affecting severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. The virus entry and replication in the lung cells also have a rhythmic cycle, suggesting circadian processes can affect the virus's life cycle.

22 Mar 2021

New treatment for late-stage neuroendocrine tumors found to be more effective and less toxic

A new treatment for late-stage neuroendocrine tumors (NETs) has been found to be more effective and have fewer side effects than the current standard of care, according to research published in the March issue of The Journal of Nuclear Medicine.

22 Mar 2021

YAP inhibitors could facilitate targeted treatment of basal-like breast cancer

Targeted treatment of basal-like breast cancer could be facilitated by YAP inhibitors in the future. As reported by an MDC team headed by Walter Birchmeier in the scientific journal Cancer Research, this type of cancer requires the support of the YAP protein to stimulate the growth of cancer stem cells.

22 Mar 2021

Anti-androgen drugs may help disarm coronavirus spike protein, stop progression of COVID-19

Hormone drugs that reduce androgen levels may help disarm the coronavirus spike protein used to infect cells and stop the progression of severe COVID-19 disease, suggests a new preclinical study from researchers in the Abramson Cancer Center at the University of Pennsylvania and published online in Cell Press's iScience.

22 Mar 2021

A green tea compound shows anti-SARS-CoV-2 properties in vitro

Researchers show the antiviral potential of a green tea compound against SARS-CoV-2 infection.

22 Mar 2021

SARS-CoV-2 variants develop resistance against type I interferons

A study conducted at the University of Colorado and National Institutes of Health, USA, has revealed that the resistance developed by newly emerging variants of SARS-CoV-2 against host interferon responses could serve as a potential driving force for viral evolution.

22 Mar 2021

Male fertility and androgen production may be impacted by COVID-19

An interesting new study has appeared online in the journal Hormones that discusses the effects of COVID-19 on the male and female gonads.

22 Mar 2021

Could nanoparticle vaccines offer broad protection against sarbecoviruses?

To understand the ability of SARS-CoV-2 vaccine-elicited antibodies to neutralize and protect against emerging variants (that are pathogenic) and other sarbecoviruses, a large team of researchers studied immunity by receptor-binding domain nanoparticle vaccines. They showed that a clinical-stage multivalent SARS-CoV-2 receptor-binding domain nanoparticle vaccine (SARS-CoV-2 RBD-NP) protected mice from the SARS-CoV-2-induced disease.

22 Mar 2021

Circular RNA vaccine shows neutralizing activity against B.1.351 variant

New preclinical research led by Wensheng Wei from Peking University in China has proposed the development of a circular RNA vaccine. Their findings showed the circular RNA vaccine creates neutralizing antibodies and strong T-cell responses against the receptor-binding domain of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein.

21 Mar 2021

ChAdOx1 nCoV-19 offers less protection against South African SARS-CoV-2 variant

The results of a double-blind, randomized, multisite placebo-controlled trial that was conducted in South Africa show that Oxford’s ChAdOx1 nCoV-19 (AZD1222) vaccine has no efficacy against the B.1.351 variant in preventing mild-to-moderate coronavirus disease 2019 (COVID-19), and shows reduced neutralization properties of developed antibodies. The findings are published in the New England Journal of Medicine.

21 Mar 2021

Receptor News and Research

Speakers Announced for Virtual Experimental Biology 2021 Meeting

Study suggests SARS-CoV-2 antibodies in breast milk are robust, neutralizing and durable

Dandelion extract inhibits SARS-CoV-2 in vitro

IONTAS identifies novel SARS-CoV-2 neutralising antibodies

Researchers use layered double hydroxide to increase neuronal growth in mice with spinal cord injuries

Ai helps identify critical interactions for SARS-CoV-2 spike protein binding to ACE2

Single BNT162b2 mRNA dose induces humoral and T cell responses against mutated variants with a history of COVID-19

Simple SARS-CoV-2 mutations allow escape from the majority of polyclonal antibodies

Star-shaped brain cells impact the length and depth of sleep in mice

Virginia Tech neuroscientist uses NIH grant to understand astrocytic processes in the healthy brain

SARS-CoV-2 infection is circadian

New treatment for late-stage neuroendocrine tumors found to be more effective and less toxic

YAP inhibitors could facilitate targeted treatment of basal-like breast cancer

Anti-androgen drugs may help disarm coronavirus spike protein, stop progression of COVID-19

A green tea compound shows anti-SARS-CoV-2 properties in vitro

SARS-CoV-2 variants develop resistance against type I interferons

Male fertility and androgen production may be impacted by COVID-19

Could nanoparticle vaccines offer broad protection against sarbecoviruses?

Circular RNA vaccine shows neutralizing activity against B.1.351 variant

ChAdOx1 nCoV-19 offers less protection against South African SARS-CoV-2 variant

Event guide: 4th Extra-Hepatic Lipid-Based Nanoparticles Delivery Summit eBook

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News